110 related articles for article (PubMed ID: 1512936)
21. [Ciprofloxacin by the intravenous route in the treatment of respiratory infections].
Mangiarotti P; Manara G; Bianchi L; Piccioni PD; Grassi C
G Ital Chemioter; 1989; 36(1-3):89-94. PubMed ID: 2488917
[TBL] [Abstract][Full Text] [Related]
22. Clinical efficacy of ciprofloxacin in the treatment of patients with respiratory tract infections in Japan.
Kobayashi H
Am J Med; 1987 Apr; 82(4A):169-73. PubMed ID: 3555031
[TBL] [Abstract][Full Text] [Related]
23. Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes.
Chono S; Tanino T; Seki T; Morimoto K
J Drug Target; 2006 Sep; 14(8):557-66. PubMed ID: 17043040
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis.
Stutman HR; Shalit I; Marks MI; Greenwood R; Chartrand SA; Hilman BC
Am J Med; 1987 Apr; 82(4A):142-5. PubMed ID: 3555028
[TBL] [Abstract][Full Text] [Related]
25. [Effectiveness of ciprofloxacin in the treatment of hospital infections of the lower respiratory tract].
Chuchalin AG; Novikov IuK; Avdeev SN; Belevskiĭ AS
Antibiot Khimioter; 1997; 42(6):34-8. PubMed ID: 9313057
[TBL] [Abstract][Full Text] [Related]
26. The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing.
Begg EJ; Robson RA; Saunders DA; Graham GG; Buttimore RC; Neill AM; Town GI
Br J Clin Pharmacol; 2000 Jan; 49(1):32-8. PubMed ID: 10606835
[TBL] [Abstract][Full Text] [Related]
27. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
Stass H; Delesen H; Nagelschmitz J; Staab D
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
[TBL] [Abstract][Full Text] [Related]
28. [Levofloxacin concentrations in serum, sputum and lung tissue: evaluation of its efficacy according to breakpoint].
Fujita A; Miya T; Tanaka R; Hirayama S; Isaka H; Ono Y; Koshiishi Y; Goya T
Jpn J Antibiot; 1999 Nov; 52(11):661-6. PubMed ID: 10659442
[TBL] [Abstract][Full Text] [Related]
29. Single and multiple dose pharmacokinetics of oral ciprofloxacin in elderly patients.
Guay DR; Awni WM; Peterson PK; Obaid S; Stein D; Breitenbucher R; Matzke GR
Int J Clin Pharmacol Ther Toxicol; 1988 Jun; 26(6):279-84. PubMed ID: 3410603
[TBL] [Abstract][Full Text] [Related]
30. Efficient drug delivery to lung epithelial lining fluid by aerosolization of ciprofloxacin incorporated into PEGylated liposomes for treatment of respiratory infections.
Chono S; Suzuki H; Togami K; Morimoto K
Drug Dev Ind Pharm; 2011 Apr; 37(4):367-72. PubMed ID: 20815792
[TBL] [Abstract][Full Text] [Related]
31. [Clinical evaluation of sulbactam/cefoperazone in lower respiratory tract infections].
Ishibashi T; Takamoto M; Shinoda A; Yoshida M; Ichikawa Y; Kido M; Ninomiya K; Kitahara Y; Hara N; Tsurutani H
Jpn J Antibiot; 1990 Feb; 43(2):239-56. PubMed ID: 2194054
[TBL] [Abstract][Full Text] [Related]
32. Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections.
Nix DE; Sands MF; Peloquin CA; Vari AJ; Cumbo TJ; Vance JW; Fracasso JE; Schentag JJ
Am J Med; 1987 Apr; 82(4A):352-6. PubMed ID: 3555060
[TBL] [Abstract][Full Text] [Related]
33. Prospective study of lower respiratory tract infections in an extended-care nursing home program: potential role of oral ciprofloxacin.
Peterson PK; Stein D; Guay DR; Logan G; Obaid S; Gruninger R; Davies S; Breitenbucher R
Am J Med; 1988 Aug; 85(2):164-71. PubMed ID: 3041830
[TBL] [Abstract][Full Text] [Related]
34. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1996)].
Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Shimizu Y; Terai T; Inoue H; Nakadate T; Ito C; Yoshida T; Ohno I; Tanno Y; Arakawa M; Igarashi K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Nakata K; Nakatani T; Inagawa H; Kusano N
Jpn J Antibiot; 1998 Jul; 51(7):437-74. PubMed ID: 9755430
[TBL] [Abstract][Full Text] [Related]
35. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
[TBL] [Abstract][Full Text] [Related]
36. [Clinical evaluation of sisomicin following intravenous drip infusion in respiratory tract infections].
Nagahama F; Ito R; Sasaki Y; Ohashi R; Shimomura J; Sasaki N; Osaki Y; Yozawa K; Tamura T; Isobe H
Jpn J Antibiot; 1985 Jun; 38(6):1533-51. PubMed ID: 4046175
[TBL] [Abstract][Full Text] [Related]
37. [Ciprofloxacin: an alternative oral treatment in respiratory Pseudomonas infection in cystic fibrosis].
Magni A; Pradal U; Cazzola G; Mastella G
Pediatr Med Chir; 1990; 12(5):531-4. PubMed ID: 2087426
[TBL] [Abstract][Full Text] [Related]
38. [Clinical evaluation of cefoperazone in lower respiratory tract infections].
Ishibashi T; Takamoto M; Shinoda A; Matsuba K; Yoshida M; Ichikawa Y; Ando M; Matsuzaki Y; Kitahara Y; Hara N
Jpn J Antibiot; 1986 Oct; 39(10):2780-94. PubMed ID: 3543433
[TBL] [Abstract][Full Text] [Related]
39. [Nationwide sensitivity surveillance of ciprofloxacin and various parenteral antibiotics against bacteria isolated from patients with severe infections--the first Ciproxan IV special investigation in 2001].
Yamaguchi K; Ishii Y; Iinuma Y; Yamanaka K; Ichiyama S; Watanabe N; Uehara N; Kaku M; Kurokawa Y; Hayashi M; Hirakata Y
Jpn J Antibiot; 2003 Dec; 56(6):546-73. PubMed ID: 15007872
[TBL] [Abstract][Full Text] [Related]
40. A randomized study comparing low dose ciprofloxacin and ofloxacin in the treatment of lower respiratory tract infections.
Polubiec A; Jórasz I; Pietrzak J; Soszka A; Stepka K; Zaryn A
Infection; 1994; 22(1):62-4. PubMed ID: 8181847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
